Phase II Study of Arimoclomol in IBM FDA-OOPD

Authors :: Mamatha Pasnoor
Rabi Tawil
Bill Martens
Linda Greensmith
Omar Jawdat
Mazen M. Dimachkie
Michael P. McDermott
Melanie Glenn
Pedro Machado
Richard J. Barohn
J. Statland
April McVey
Laura Herbelin
Michael G. Hanna
Source :: RRNMF Neuromuscular Journal. 2
Publication Year :: 2021
Publisher :: The University of Kansas, 2021.

Subjects :: Oncology
chemistry.chemical_compound
medicine.medical_specialty
chemistry
business.industry
Internal medicine
medicine
General Medicine
Arimoclomol
IBM
Inclusion body myositis
medicine.disease
business

Full Text Access

Tools